Terrosa 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0027/G 
This was an application for a group of variations. 
03/02/2023 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
manufacturer of a novel excipient 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
II/0026/G 
This was an application for a group of variations. 
10/11/2022 
SmPC, 
The SmPC sections 1, 2, 4.2, 6.4, 6.5 and 6.6 have been 
Please refer to the Recommendations section 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
Labelling and 
updated to reflect the addition of the new pre-filled pens 
PL 
presentations (EU/1/16/1159/004-005) or adapted to 
address the specific features of the pre-filled pen 
presentation.  
The Labelling and PL have been updated accordingly. The 
package leaflet contains a Pen user manual for the Terrosa 
20 micrograms (µg)/80 microliters solution for injection, in 
pre-filled pen. 
Page 2/8 
 
 
 
 
 
 
 
 
 
product - Addition of a new test(s) and limits 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.IV.1.c - Change of a measuring or administration 
device - Addition or replacement of a device which is 
an integrated part of the primary packaging 
PSUSA/2903/
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
202109 
teriparatide 
IB/0024/G 
This was an application for a group of variations. 
13/12/2021 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0023 
B.I.a.2.z - Changes in the manufacturing process of 
02/12/2021 
n/a 
the AS - Other variation 
R/0020 
Renewal of the marketing authorisation. 
22/07/2021 
16/09/2021 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Terrosa in the approved indication remains favourable and 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0021/G 
This was an application for a group of variations. 
06/08/2021 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
IB/0019/G 
This was an application for a group of variations. 
07/01/2021 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
II/0018 
B.II.e.1.a.3 - Change in immediate packaging of the 
17/09/2020 
16/09/2021 
SmPC, Annex 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
II, Labelling 
and PL 
IB/0016/G 
This was an application for a group of variations. 
17/04/2020 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. The RMP has been 
also updated (version 2.2). 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
IAIN/0017 
B.IV.1.a.1 - Change of a measuring or administration 
10/04/2020 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IB/0014 
B.II.b.5.z - Change to in-process tests or limits 
09/01/2020 
n/a 
applied during the manufacture of the finished 
product - Other variation 
N/0013 
Minor change in labelling or package leaflet not 
30/12/2019 
09/03/2020 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IA/0012 
B.II.e.6.b - Change in any part of the (primary) 
26/06/2019 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
II/0009 
Submission of the final clinical study report from 
14/06/2019 
n/a 
n/a 
Study RGB1023O31; a Phase III, multi-centre, 
randomised, active-controlled, parallel-group, 
comparative efficacy/safety study. An updated RMP 
version 1.4 was agreed during the procedure. 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IA/0011 
A.5.b - Administrative change - Change in the name 
24/05/2019 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
II/0010 
B.II.e.1.a.3 - Change in immediate packaging of the 
23/05/2019 
n/a 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
PSUSA/2903/
Periodic Safety Update EU Single assessment - 
16/05/2019 
n/a 
PRAC Recommendation - maintenance 
201809 
teriparatide 
IB/0006 
B.IV.1.a.1 - Change of a measuring or administration 
26/03/2019 
09/03/2020 
SmPC, 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
Labelling and 
PL 
IA/0007 
B.II.d.2.a - Change in test procedure for the finished 
18/12/2018 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0005/G 
This was an application for a group of variations. 
30/10/2018 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.z - Quality change - Active substance - Other 
variation 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.2.a.2 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - Excipient/AS starting material 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/02/2018 
07/02/2019 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
IA/0003 
A.z - Administrative change - Other variation 
05/04/2017 
05/03/2018 
SmPC, 
Labelling and 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
IB/0001/G 
This was an application for a group of variations. 
05/04/2017 
n/a 
PL 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
